Cargando…

P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C

Detalles Bibliográficos
Autores principales:	Alsina, Melissa, Dhodapkar, Madhav, Berdeja, Jesus, Patel, Krina, Richard, Shambavi, Vij, Ravi, Leleu, Xavier, Egan, Daniel, Leif Bergsagel, P., Ran, Reshef, Usmani, Saad Z, Truppel-Hartmann, Anna, Basudhar, Debashree, Thompson, Ethan, Zheng, Xirong, Zhong, Xiaobo, Greggio, Chiara, Popa Mckiver, Mihaela, Carrasco Alfonso, Marlene, Siegel, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431112/ http://dx.doi.org/10.1097/01.HS9.0000970388.90596.a3

Ejemplares similares

P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
por: Piasecki, Julia, et al.
Publicado: (2023)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS
por: Patel, Krina, et al.
Publicado: (2023)

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
por: Delforge, Michel, et al.
Publicado: (2023)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
por: Jagannath, Sundar, et al.
Publicado: (2021)

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
por: Manier, Salomon, et al.
Publicado: (2023)

Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
por: McGarvey, November, et al.
Publicado: (2023)

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
por: Rodríguez-Otero, P., et al.
Publicado: (2023)

P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE
por: Martin, N., et al.
Publicado: (2022)

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
por: Minakata, Daisuke, et al.
Publicado: (2023)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
por: Sanoyan, Dilara Akhoundova, et al.
Publicado: (2023)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
por: Oriol, Albert, et al.
Publicado: (2021)

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS
por: Mashadi-Hossein, Afshin, et al.
Publicado: (2023)

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023)

Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
por: Connarn, Jamie N., et al.
Publicado: (2023)

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
por: Logue, Jennifer M., et al.
Publicado: (2022)

Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
por: Oswald, Laura B., et al.
Publicado: (2023)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
por: Lin, Yi, et al.
Publicado: (2023)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

P866: CORRELATIVE ANALYSIS TO DEFINE PATIENT PROFILES ASSOCIATED WITH MANUFACTURING AND CLINICAL ENDPOINTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (BB2121)
por: Rytlewski, J., et al.
Publicado: (2022)

P1740: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS BELANTAMAB MAFODOTIN: A MATCHING-ADJUSTED INDIRECT COMPARISON STUDY
por: Shah, N., et al.
Publicado: (2022)

Correction to Lancet Psychiatry 2021; 8: 871–82
Publicado: (2022)

Correction to Lancet Psychiatry 2021; 8: 871–82
Publicado: (2022)

Functional and Kinetic Comparison of Alanine Cysteine Serine Transporters ASCT1 and ASCT2
por: Wang, Jiali, et al.
Publicado: (2022)

Mar cel Levi
por: Baltesen, Frits
Publicado: (2021)

Pathogenic Carboxyl Ester Lipase (CEL) Variants Interact with the Normal CEL Protein in Pancreatic Cells
por: Dalva, Monica, et al.
Publicado: (2020)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine‐addicted OSCC cells
por: Luo, Yijun, et al.
Publicado: (2020)

Expression, Characterization and Synergistic Interactions of Myxobacter Sp. AL-1 Cel9 and Cel48 Glycosyl Hydrolases
por: Ramírez-Ramírez, Norma, et al.
Publicado: (2008)

ASCT2 is the primary serine transporter in cancer cells
por: Conger, Kelly O., et al.
Publicado: (2023)

Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands
por: Jin, Sheng Chih, et al.
Publicado: (2017)

Cel i terra : l'art dels cartógrafs a la Universitat de Valéncia /
Publicado: (1996)

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
por: Maloney, David G., et al.
Publicado: (2021)

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
por: Sun, Hong-Wei, et al.
Publicado: (2016)

Genomic ancestry and ethnoracial self-classification based on 5,871 community-dwelling Brazilians (The Epigen Initiative)
por: Lima-Costa, M. Fernanda, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_aggcmbungoovdr810s8fpqdfdl